|Articles|May 4, 2012

Paul Dobesh, PharmD, Points Out the Benefits of Combining Anticoagulant and Antiplatelet Treatments

Dr. Dobesh addresses the challenges of achieving efficacy without having the patient bleed when combining anticoagulant and antiplatelet treatments.

Paul Dobesh, PharmD, addresses the challenges in trying to simplify medication regiments in cardiovascular disease to improve clinical outcomes and increase adherence.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Paul Dobesh, PharmD, Points Out the Benefits of Combining Anticoagulant and Antiplatelet Treatments

Related Content

Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD

Communication Is Key to Successful Cell Therapy Trials: Bridget Keenan, MD, PhD

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

Site of Care, TDM Still Shape AYA ALL Outcomes: Emily K. Curran, MD

Tobevibart Combo Shows High Hepatitis D Efficacy: Tarik Asselah, MD, PhD

Trending on AJMC

FDA Approves Novel Iberdomide Regimen in RRMM

Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD

IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds

AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk

Topical Delgocitinib Rivals Dupilumab for Hand Eczema, but Adherence Is Key